drugset / Trial / NCT01181973
Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
RandomizedCrossoverOpen-labelBasic science
Summary
The hypothesis to be tested is that the bioavailability of the new 30-mg vial is similar to that of the current approved 15 -mg vials. In addition, the SC injection using the new 30-mg vial is safe and well-tolerated.
Timeline
- Start
- 2010-10
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pegvisomant | Protein / enzyme biologic | 15 mg | Subcutaneous |
| Comparator | Pegvisomant | Protein / enzyme biologic | 30 mg | Subcutaneous |
Indications
No indication recorded.